Scinai Immunotherapeutics Ltd..
SCNI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing and commercializing innovative immunotherapies. The company's primary focus is on developing treatments for immune-mediated diseases and cancer. This involves research and development activities, including preclinica...Show More
Better Health for All
0
Scinai Immunotherapeutics is entirely devoted to health improvement, focusing on developing immunotherapies for severe dermatological conditions like Pemphigus, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and plaque psoriasis. One product, PC111, has Orphan Drug Designation.
1
The company has no revenue from products with significant negative health impacts.
2
While the company is investing in R&D for its nanoAbs pipeline and has a €12 million grant application for PC111's development, no specific percentage of the R&D budget allocated to health improvement is provided.
3
The company notes that forward-looking statements carry risks detailed in SEC filings, indicating comprehensive risk disclosures.
4
The Paul Ehrlich Institute (PEI) has agreed to the clinical trial design for SCN-1, including patient selection and comparison to placebo, and accepted toxicology studies in pigs instead of non-human primates.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Scinai Immunotherapeutics Ltd. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage is not available.
1
While executive compensation figures are provided, median employee compensation is not, preventing the calculation of the CEO median pay ratio.
2
Regulatory compliance issues mentioned relate to financial filings and Nasdaq listing rules, not labor law or human rights violations.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Scinai Immunotherapeutics Ltd. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company has a formal whistle-blower policy that allows for confidential and anonymous submissions by employees, with reporting channels to supervisors, the Audit Committee Chairman, and the Internal Auditor.
1
Retaliation against whistle-blowers is prohibited.
2
An anti-corruption policy is in place, prohibiting bribes, kickbacks, and unusual payments to foreign officials and healthcare providers, and mentions compliance with FCPA and other anti-corruption laws.
3
Kind to Animals
-60
Scinai Immunotherapeutics conducts in-vivo preclinical studies using SCID-Beige mice and plans further in-vivo animal studies and preclinical toxicology studies for late 2024.
1
The company uses alternative testing methods, including ex-vivo studies with human skin specimens, in vitro models with human skin tissue, and a 3D biologic skin model.
2
The Paul Erlich Institute (PEI) accepted Scinai's position to conduct toxicology studies in pigs rather than Non-Human Primates.
3
Scinai collaborates with Prof. Amos Gilhar and his team at the Technion, Israel Institute of Technology, and Genoskin for in-vivo and ex-vivo studies, respectively.
4
They also collaborated with the Max Planck Institute and University Medical Center Göttingen for NanoAb testing.
5
Scinai had a Scientific Advice meeting with the PEI regarding its drug development program.
6
The company's R&D budget allocation to animal-free technologies is not specified, but the use of alternatives is mentioned in the context of specific studies, not as a dedicated investment percentage. The company does not explicitly mention an animal testing policy, but its actions indicate that legal mandates for animal testing override alternatives.
7
No War, No Weapons
0
No specific, quantitative, or verifiable evidence was found in the provided articles for any of the KPIs related to the 'No War, No Weapons' ethical value. The articles describe the company's biopharmaceutical focus and general Code of Conduct, but do not contain data on arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other metrics required by the rubric.
1
explicitly states that it does not contain quantitative data relevant to arms contracts or peacebuilding activities.
2
Planet-Friendly Business
-20
The company reported zero environmental compliance violations in Q1 2025, and no regulatory actions, violations, fines, or compliance issues were mentioned in its Q1 2025, full year 2024, or 2023 financial summaries.
1
No other planet-friendly business metrics were disclosed in the provided articles.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Scinai Immunotherapeutics Ltd.'s respect for cultures and communities. The articles primarily focus on financial results, operational updates, and career opportunities, without addressing community engagement, cultural impact assessments, local employment ratios, grievance mechanisms, or any other metrics related to this ethical value.
Safe & Smart Tech
0
The company's privacy policy, updated on September 5, 2023, indicates that users have the ability to request access, correction, deletion, and restriction of their data, and can unsubscribe from email alerts.
1
The policy also states a commitment to GDPR compliance and user rights.
2
Zero Waste & Sustainable Products
0
No specific, quantitative data points were found in the provided articles for SCNI.US regarding waste management, product sustainability, or circular economy practices.
1
The articles discuss general medical waste issues in Israel
2
and a specific medical waste treatment machine (Envomed 80),
3
but do not link these to SCNI.US's operations or performance metrics. Company-specific articles explicitly state that no sustainability metrics are mentioned.
4